Current and Future Considerations in the Treatment of Relapsed/Refractory Multiple Myeloma

Relapsed/Refractory Multiple Myeloma: Disease Overview

March 12th 2021

A historical review of treatment advances in relapsed/refractory multiple myeloma and criteria used to define relapsed or refractory disease.

Treatment Pathways for Relapsed/Refractory Myeloma

March 12th 2021

Factors that influence treatment selection for relapsed or refractory multiple myeloma, and suggestions to help streamline decision making and address limitations associated with current treatment pathways.

IV Versus Subcutaneous Daratumumab

March 12th 2021

Healthcare stakeholders comment on current practices managing patients with relapsed/refractory multiple myeloma during the COVID pandemic and discuss their comfort switching patients over from intravenous daratumumab to subcutaneous daratumumab.

Backbone Regimens for Relapsed/Refractory Myeloma

March 12th 2021

Variables considered by healthcare professionals when selecting an appropriate backbone regimen to manage a patient with relapsed or refractory multiple myeloma.

mAb-based Therapies for Relapsed/Refractory Myeloma

March 12th 2021

Considerations for treating patients with relapsed/refractory multiple myeloma with elotuzumab, daratumumab, or isatuximab based on more recent clinical trial data and differences between each treatment option.

Novel Agents for Relapsed/Refractory Myeloma

March 12th 2021

Best practices for prescribing an immunomodulatory-based therapy or a proteasome inhibitor as treatment for relapsed/refractory multiple myeloma.

Belantamab Mafodotin for RRMM

March 17th 2021

Recommendations for managing patients who receive belantamab mafodotin, an anti-BCMA therapy, for relapsed/refractory multiple myeloma, with special considerations regarding the ocular health of patients.

RRMM: Adopting Anti-BCMA Therapy into Practice

March 17th 2021

Robert Mancini, PharmD, BCOP, FHOPA, of St. Luke’s Cancer Institute: Boise, comments on his experience navigating challenges using belantamab mafodotin, an anti-BCMA therapy, to treat relapsed/refractory multiple myeloma.

RRMM: Educating Pharmacists on Anti-BCMA Therapy

March 26th 2021

The importance of coordinated care and proper education to pharmacists on best practices when dispensing anti-BMCA therapy to patients with relapsed/refractory multiple myeloma.

Clinical Trials of Interest in RRMM

March 26th 2021

Novel treatment strategies being explored in clinical trials that look exciting in relapsed/refractory multiple myeloma, and implications for using these newer approaches in the future.